Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate

被引:15
作者
Gu, CH
Gandhi, RB
Tay, LK
Zhou, S
Raghavan, K
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Biopharmaceut R&D, New Brunswick, NJ 08903 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Clin Discovery, Lawrenceville, NJ 08543 USA
关键词
bioavailability; BMS-480188; dissolution; formulation; volume of dissolution medium;
D O I
10.1016/j.ijpharm.2003.09.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BMS-480188 is a weak base. The aqueous solubility of BMS-480188 is 0.036 mg/ml at pH 6.5 at 37 degreesC. The mesylate salt of BMS-480188 was prepared to improve its solubility. Capsules containing mesylate salt alone (Formulation A) or mesylate salt with excipients, including lactose, croscarmellose sodium, sodium lauryl sulfate, syloid and magnesium stearate (Formulation B), were prepared. Both formulations show similar dissolution profiles in 110.01N HCl at 37 degreesC. However, the bioavailability of Formulations A and B is 5.7 and 24%, respectively, in monkeys. Since very small amount of fluid is available in the stomach of monkeys in fasted state, 30 ml of 0.01N HCl was used as the dissolution medium to simulate the ratio of the drug to dissolution medium in vivo. The dissolution studies in 30 ml of 0.01N HCl show that the amount of drug dissolved from the Formulation B is 80% greater than the Formulation A after 2 h. These results are consistent with the higher bioavailability of the formulated capsules. The pK(a) of the free base is 3.0 and the apparent solubility of the mesylate salt (>20 mg/ml) is much greater than the equilibrium solubility of BMS-480188 (1.08 mg/ml) in 0.01N HCl at 37 degreesC. Therefore, the mesylate salt of BMS-480188 converts to the free base in 0.01N HCl. The presence of excipients delays the conversion of the mesylate salt to the free base in the dissolution test using 30 ml medium, leading to a greater percentage of the dissolved drugs. This inhibitory effect of excipients is masked during the dissolution using 11 medium because the concentration of the dissolved drug is below the solubility limit of BMS-480188. This study demonstrates the importance of the volume of the dissolution medium for the in vitro dissolution test to qualitatively predict the bioavailability of a salt of weak base with low intrinsic aqueous solubility. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:195 / 202
页数:8
相关论文
共 6 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]   In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs [J].
Dressman, JB ;
Reppas, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 :S73-S80
[3]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[4]   Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs [J].
Galia, E ;
Nicolaides, E ;
Hörter, D ;
Löbenberg, R ;
Reppas, C ;
Dressman, JB .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :698-705
[5]   COMPARISON OF THE GASTROINTESTINAL ANATOMY, PHYSIOLOGY, AND BIOCHEMISTRY OF HUMANS AND COMMONLY USED LABORATORY-ANIMALS [J].
KARARLI, TT .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1995, 16 (05) :351-380
[6]   Effect of common excipients on Caco-2 transport of low-permeability drugs [J].
Rege, BD ;
Yu, LX ;
Husain, AS ;
Polli, JE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) :1776-1786